Recursion Pharmaceuticals
clinical enrollment criteria outcome measures trial update poplar phase underway | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
104 of 143
Related slides by other companies
MindMed
Investor Presentation
November 2024
phase gad part schematics extension phase voyage a panorama | MindMed
ATAI
Investor Presentation
January 2024
trial status first patient dosed in topline data anticipated mid clinical design phase study | ATAI
ATAI
Investor Presentation
October 2023
trial status first patient dosed in topline data anticipated clinical design phase study | ATAI
BenevolentAI
Investor Presentation
October 2022
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights